{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T06:54:12Z","timestamp":1777964052803,"version":"3.51.4"},"reference-count":30,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T00:00:00Z","timestamp":1586995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2020,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>The purpose of this study was to examine the incidence of Parkinsonism in new users of second\u2010generation antipsychotics (SGAs) in older adults (\u226565\u2009years). In the secondary analyses, we examined the risk of Parkinsonism by type and dose of SGA and conducted age\u2010sex interactions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>This population\u2010based study included older adults who had a new\u2010onset diagnosis of Parkinsonism and who started taking olanzapine, risperidone or quetiapine between 1 January 2005, and 30 December 2016. The Cox proportional hazard (COXPH) model with inverse probability treatment weighted (IPTW) covariates was used to evaluate the risk of new\u2010onset Parkinsonism associated with SGAs, using quetiapine as the reference. We used the Generalized Propensity Score method to evaluate the dose\u2010response risk of Parkinsonism associated with SGAs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>After IPTW adjustment for covariates, the COXPH model showed that compared to quetiapine, the use of olanzapine and risperidone were associated with an increased risk of Parkinsonism. The IPTW\u2010hazard ratios are 1.76 (95% confidence interval 1.57\u20101.97) and 1.31 (95%CI 1.16\u20101.49), respectively. The dose\u2010response risk of Parkinsonism was highest for olanzapine with a hazard ratio of 1.69 (95%CI 1.40\u20102.05) and the least for quetiapine with a hazard ratio of 1.22 (95%CI 1.14\u20101.31). The risk of Parkinsonism in the 65 to 74\u2010year age group was higher for both sexes with risperidone compared to olanzapine, but the risk increased with olanzapine for both sexes in the 85+ age group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The study found that the risk of new\u2010onset Parkinsonism in older adults is 31% and 76% higher with risperidone and olanzapine respectively compared to quetiapine.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.5007","type":"journal-article","created":{"date-parts":[[2020,4,17]],"date-time":"2020-04-17T05:49:59Z","timestamp":1587102599000},"page":"692-700","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparative risk of Parkinsonism associated with olanzapine, risperidone and quetiapine in older adults\u2010a propensity score matched cohort study"],"prefix":"10.1002","volume":"29","author":[{"given":"Te\u2010yuan","family":"Chyou","sequence":"first","affiliation":[{"name":"Department of Biochemistry University of Otago  Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Revathi","family":"Nishtala","sequence":"additional","affiliation":[{"name":"Leeds School of Medicine University of Leeds  Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4155-8540","authenticated-orcid":false,"given":"Prasad S.","family":"Nishtala","sequence":"additional","affiliation":[{"name":"Department of Pharmacy &amp; Pharmacology University of Bath  Bath UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,4,16]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-014-0205-1"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117714047"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-012-0013-4"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002512-200623120-00002"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200528030-00002"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200216010-00003"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjopharm.2012.11.001"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-015-1023-4"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.297.11.1233"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1997.tb02960.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/656370"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.312.7040.1215"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)07451-2"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.16.1882"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0064217"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"e_1_2_10_18_1","unstructured":"Pharmaceutical Management Agency (PHARMAC). How medicines are funded. Retrieved on 26 July2019fromhttps:\/\/www.pharmac.govt.nz\/medicines\/how-medicines-are-funded\/"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.3.360"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31135-3"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-017-2333-0"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.5753"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.6607"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.econlet.2013.01.006"},{"key":"e_1_2_10_25_1","unstructured":"R Core Team(2018). R: a language and environment for statistical computing. R Foundation for Statistical Computing Vienna Austria. Retrieved fromhttps:\/\/www.R-project.org\/"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-002-1082-6"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(00)00911-5"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-9964(98)00105-4"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.26839"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/58.1.M94-a"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/mds.21854"}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.5007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5007","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pds.5007","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.5007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,30]],"date-time":"2023-08-30T13:39:18Z","timestamp":1693402758000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.5007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,16]]},"references-count":30,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["10.1002\/pds.5007"],"URL":"https:\/\/doi.org\/10.1002\/pds.5007","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,16]]},"assertion":[{"value":"2020-01-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-03-29","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-16","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}